Tvardi Therapeutics (TVRD)

• Market cap: $25M
• 1 day: 1.14%
• 5 days: -6.64%
• 1 month: -33.25%
• 3 months: -31.36%
• 6 months: -36.73%
• Year to date: -34.56%
• 1 year: -89.3%
• 5 years: -99.48%
• 10 years: -98.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Employees: 12